The Impact of COVID-19 on Access to Parkinson's Disease Medication.
Mov Disord
; 35(12): 2129-2133, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32860226
ABSTRACT
BACKGROUND:
Many countries have implemented drastic measures to fight the COVID-19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID-19 had an impact on access to PD medication by region and income.METHODS:
This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally.RESULTS:
Of 346 responses, 157 (45.4%) agreed that COVID-19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high-income and 88.9% of low-income countries' respondents agreed that access to PD medication was affected by COVID-19. 59% of all 'yes' respondents reported increased disability of patients as an impact.CONCLUSIONS:
Access to PD medication is likely to have been affected by COVID-19 and result in deterioration of patients' symptomatic control. Resource-poor countries appear to be disproportionately affected compared to more affluent countries. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
SARS-CoV-2
/
COVID-19
Limite:
Humans
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article